Recursion Pharmaceuticals ( (RXRX) ) has provided an announcement.
On February 28, 2025, Recursion Pharmaceuticals released its fourth-quarter and fiscal year 2024 financial results, highlighting significant advancements in its clinical pipeline and strategic partnerships. The company reported promising data for its drug candidates REC-617 and REC-994, initiated new clinical studies, and achieved substantial milestones with partners like Roche, Genentech, and Sanofi, generating $45 million in cash inflows. Additionally, Recursion completed a business combination with Exscientia, enhancing its position as a leading TechBio company with a robust portfolio of clinical and preclinical programs.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals is a leading clinical-stage TechBio company focused on decoding biology to radically improve lives. The company leverages a full-stack AI-powered platform, Recursion OS, to drive drug discovery and development across various therapeutic areas, including oncology, rare diseases, and infectious diseases.
YTD Price Performance: 6.38%
Average Trading Volume: 22,495,257
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3B
See more insights into RXRX stock on TipRanks’ Stock Analysis page.